| __timestamp | Travere Therapeutics, Inc. | Zoetis Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 47795223 | 396000000 |
| Thursday, January 1, 2015 | 50426000 | 364000000 |
| Friday, January 1, 2016 | 70853000 | 376000000 |
| Sunday, January 1, 2017 | 78168000 | 382000000 |
| Monday, January 1, 2018 | 123757000 | 432000000 |
| Tuesday, January 1, 2019 | 140963000 | 457000000 |
| Wednesday, January 1, 2020 | 131773000 | 463000000 |
| Friday, January 1, 2021 | 210328000 | 508000000 |
| Saturday, January 1, 2022 | 235780000 | 539000000 |
| Sunday, January 1, 2023 | 244990000 | 614000000 |
| Monday, January 1, 2024 | 686000000 |
Unlocking the unknown
In the ever-evolving landscape of biopharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, Zoetis Inc. and Travere Therapeutics, Inc. have demonstrated contrasting yet compelling R&D investment strategies.
Zoetis Inc., a leader in animal health, has consistently increased its R&D spending, culminating in a 55% rise from 2014 to 2023. This steady growth underscores Zoetis's commitment to pioneering veterinary solutions.
Conversely, Travere Therapeutics, Inc. has seen a dramatic 412% increase in R&D expenses over the same period. This surge reflects Travere's aggressive pursuit of novel therapies for rare diseases.
Both companies exemplify the critical role of R&D in driving biopharmaceutical advancements, albeit through distinct approaches.
Eli Lilly and Company or Travere Therapeutics, Inc.: Who Invests More in Innovation?
R&D Spending Showdown: Pfizer Inc. vs Zoetis Inc.
Comparing Innovation Spending: Sanofi and Travere Therapeutics, Inc.
R&D Spending Showdown: Zoetis Inc. vs Dr. Reddy's Laboratories Limited
Research and Development Investment: Zoetis Inc. vs Vericel Corporation
Who Prioritizes Innovation? R&D Spending Compared for Incyte Corporation and Travere Therapeutics, Inc.
Research and Development: Comparing Key Metrics for Summit Therapeutics Inc. and Travere Therapeutics, Inc.
R&D Insights: How Alpine Immune Sciences, Inc. and Travere Therapeutics, Inc. Allocate Funds
Comparing Innovation Spending: Ultragenyx Pharmaceutical Inc. and Travere Therapeutics, Inc.
Comparing Innovation Spending: CRISPR Therapeutics AG and Travere Therapeutics, Inc.
Research and Development: Comparing Key Metrics for Amicus Therapeutics, Inc. and Travere Therapeutics, Inc.
Comparing Innovation Spending: Supernus Pharmaceuticals, Inc. and Travere Therapeutics, Inc.